EPMA position paper in cancer: current overview and future perspectives

被引:73
作者
Grech, Godfrey [1 ]
Zhan, Xianquan [2 ]
Yoo, Byong Chul [3 ]
Bubnov, Rostyslav [4 ,5 ]
Hagan, Suzanne [6 ]
Danesi, Romano [7 ]
Vittadini, Giorgio [8 ]
Desiderio, Dominic M. [9 ]
机构
[1] Univ Malta, Fac Med & Surg, Dept Pathol, Msida, Malta
[2] Cent South Univ, Xiangya Hosp, Chinese Minist Hlth, Key Lab Canc Prote, Changsha, Hunan, Peoples R China
[3] Natl Canc Ctr, Res Inst, Div Translat & Clin Res 1, Colorectal Canc Branch, Gyeonggi 410769, South Korea
[4] Clin Hosp Pheophania, State Management Affairs Dept, Kiev, Ukraine
[5] Natl Acad Sci Ukraine, Zabolotny Inst Microbiol & Virol, Kiev, Ukraine
[6] Glasgow Caledonian Univ, Dept Life Sci, Sch Hlth & Life Sci, Glasgow G4 0BA, Lanark, Scotland
[7] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[8] Ctr Ric Bracco, Bracco Imaging, San Donato Milanese, Italy
[9] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA
关键词
Predictive preventive personalized medicine; Risk assessment; Expert recommendation; Standardization; Individual profile; Disease modeling; Multimodal diagnostics; Screening; Biomarker; Biobank; CELL LUNG-CANCER; GENOME-WIDE ASSOCIATION; TUMOR-SUPPRESSOR GENE; HUMAN-BREAST-CANCER; SINGLE-NUCLEOTIDE POLYMORPHISMS; HUMAN HEPATOCELLULAR-CARCINOMA; SPECTROMETRY-BASED PROTEOMICS; METASTATIC COLORECTAL-CANCER; TYROSINE KINASE INHIBITORS; ENDOTHELIAL GROWTH-FACTOR;
D O I
10.1186/s13167-015-0030-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare. During the development of PPPM, many rapid, specific, and sensitive new methods for earlier detection of cancer will result in more efficient management of the patient and hence a better quality of life. Coordination of the various activities among different healthcare professionals in primary, secondary, and tertiary care requires well-defined competencies, implementation of training and educational programs, sharing of data, and harmonized guidelines. In this position paper, the current knowledge to understand cancer predisposition and risk factors, the cellular biology of cancer, predictive markers and treatment outcome, the improvement in technologies in screening and diagnosis, and provision of better drug development solutions are discussed in the context of a better implementation of personalized medicine. Recognition of the major risk factors for cancer initiation is the key for preventive strategies (EPMA J. 4(1):6, 2013). Of interest, cancer predisposing syndromes in particular the monogenic subtypes that lead to cancer progression are well defined and one should focus on implementation strategies to identify individuals at risk to allow preventive measures and early screening/diagnosis. Implementation of such measures is disturbed by improper use of the data, with breach of data protection as one of the risks to be heavily controlled. Population screening requires in depth cost-benefit analysis to justify healthcare costs, and the parameters screened should provide information that allow an actionable and deliverable solution, for better healthcare provision.
引用
收藏
页数:31
相关论文
共 394 条
  • [91] Dobrovic A, 1997, CANCER RES, V57, P3347
  • [92] Review - Mass spectrometry and protein analysis
    Domon, B
    Aebersold, R
    [J]. SCIENCE, 2006, 312 (5771) : 212 - 217
  • [93] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
    Douillard, Jean-Yves
    Oliner, Kelly S.
    Siena, Salvatore
    Tabernero, Josep
    Burkes, Ronald
    Barugel, Mario
    Humblet, Yves
    Bodoky, Gyorgy
    Cunningham, David
    Jassem, Jacek
    Rivera, Fernando
    Kocakova, Ilona
    Ruff, Paul
    Blasinska-Morawiec, Maria
    Smakal, Martin
    Canon, Jean Luc
    Rother, Mark
    Williams, Richard
    Rong, Alan
    Wiezorek, Jeffrey
    Sidhu, Roger
    Patterson, Scott D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) : 1023 - 1034
  • [94] Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
    Dowsett, M
    Houghton, J
    Iden, C
    Salter, J
    Farndon, J
    A'Hern, R
    Sainsbury, R
    Baum, M
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (05) : 818 - 826
  • [95] Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study
    Dowsett, M
    Cuzick, J
    Wale, C
    Howell, T
    Houghton, J
    Baum, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7512 - 7517
  • [96] International Web-based consultation on priorities for translational breast cancer research
    Dowsett, Mitch
    Goldhirsch, Aron
    Hayes, Daniel F.
    Senn, Hans-Joerg
    Wood, William
    Viale, Giuseppe
    [J]. BREAST CANCER RESEARCH, 2007, 9 (06)
  • [97] Biochemical markers in breast cancer: which ones are clinically useful?
    Duffy, MJ
    [J]. CLINICAL BIOCHEMISTRY, 2001, 34 (05) : 347 - 352
  • [98] Duffy MJ, 2001, CLIN CHEM, V47, P624
  • [99] Too many roads not taken
    Edwards, Aled M.
    Isserlin, Ruth
    Bader, Gary D.
    Frye, Stephen V.
    Willson, Timothy M.
    Yu, Frank H.
    [J]. NATURE, 2011, 470 (7333) : 163 - 165
  • [100] Ekmektzoglou KA, 2012, ACTA GASTRO-ENT BELG, V75, P293